A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2- dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 3, 2006, Pages 1376-1385

  Honore, Prisca ^a   Donnelly Roberts, Diana ^a   Namovic, Marian T ^a   Hsieh, Gin ^a   Zhu, Chang Z ^a   Mikusa, Joe P ^a   Hernandez, Gricelda ^a   Zhong, Chengmin ^a   Gauvin, Donna M ^a   Chandran, Prasant ^a   Harris, Richard ^a   Medrano, Arturo Perez ^a   Carroll, William ^a   Marsh, Kennan ^a   Sullivan, James P ^a   Faltynek, Connie R ^a   Jarvis, Michael F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; A 740003; ADENOSINE TRIPHOSPHATE; BRILLIANT BLUE; CARRAGEENAN; INTERLEUKIN 1; ION CHANNEL; N [1 [[(CYANOIMINO)(5 QUINOLINYLAMINO)METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (3,4 DIMETHOXYPHENYL)ACETAMIDE; NEUROTRANSMITTER RECEPTOR; PEPTIDE; PURINE P2 RECEPTOR; PURINE P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; UNCLASSIFIED DRUG; VINCRISTINE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CHANNEL GATING; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG STRUCTURE; GLIA CELL; HUMAN; HUMAN CELL; HYPERALGESIA; IC 50; INFLAMMATION; MALE; MOTOR PERFORMANCE; NERVE LIGATION; NEUROPATHY; NOCICEPTION; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; SCIATIC NERVE; SPINAL NERVE; SYSTEMATIC REVIEW; TOUCH;

ACETAMIDES; ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALCIUM; CELL LINE; COLORING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FREUND'S ADJUVANT; HUMANS; HYPERALGESIA; INFLAMMATION; INTERLEUKIN-1BETA; MALE; MOTOR ACTIVITY; MUSCULOSKELETAL EQUILIBRIUM; NOCICEPTORS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2; SCIATIC NEUROPATHY; SPINAL NERVES; VINCRISTINE;

EID: 33751165071     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111559     Document Type: Article

References (55)

1. Anderson CM and Nedergaard M (2006) Emerging challenges of assigning P2X (7) receptor function and immunoreactivity in neurons. Trends Neurosci 29:257-262.
2. Armstrong JN, Brust TB, Lewis RG, and MacViar BA (2002) Activation of presynaptic P2X7-like receptors depresses mossy fiber-CA3 synaptic transmission through p38 mitogen-activated protein kinase. J Neurosci 22:5938-5945.
3. 7 receptor. J Med Chem 45:1318-1329.
4. Beigi RD, Kertesy SB, Aquilina G, and Dubyak GR (2003) Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br J Pharmacol 140:507-519.
5. Bennett GJ and Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87-107.
6. Bianchi BR, Lynch KJ, Touma E, Niforatos W, Burgard EC, Alexander KM, Park HS, Yu H, Metzger R, Kowaluk E, et al. (1999) Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol 376:127-138.
7. Bianchi M, Dib B, and Panerai AE (1998) Interleukin-1 and nociception in the rat. J Neurosci Res 53:645-650.
8. Burnstock G (2006) Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58:58-78.
9. Burnstock G and Wood JN (1996) Purinergic receptors: their role in nociception and primary afferent neurotransmission. Curr Opin Neurobiol 6:526-532.
10. 7 receptor channels, J Neurosci 22:3061-3069.
11. 7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114:386-396.
12. 7 receptor. Neuropharmacology 36:1277-1283.
13. 7 antagonist, oxidized ATP, in arthritic rats. Neurosci Lett 327:87-90.
14. 7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum 46:3378-3385.
15. 7 receptor is not the only target. Br J Pharmacol 140:441-443.
16. 7R)-induced pore formation in human THP-1 cells. J Pharmacol Exp Ther 308:1053-1061.
17. Evans RJ, Lewis C, Buell G, Vlaera S, North RA, and Surprenant A (1995) Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2X purinoceptors). Mol Pharmacol 48:178-183.
18. 7 receptor: a key player in IL-1 processing and release. J Immunol 176:3877-3883.
19. Ferreira S, Lorenzetti B, Bristow A, and Poole S (1988) Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature (Lond) 334:698-700.
20. Honore P, Wade CL, Zhong C, Harris RR, Wu C, Ghayur T, Iwakura Y, Decker MW, Faltynek C, Sullivan J, et al. (2006). Interleukin-1αβ gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain Behav Brain Res 167:355-364.
21. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, and Iwakura Y (2000) Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191:313-320.
22. 7 nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFN-γ in the human THP-1 monocytic cell line. J Immunol 157:5627-5637.
23. Jacobson KA, Jarvis MF, and Williams M (2002) Perspective: purine and pyrimidine: II. Receptors as drug targets. J Med Chem 45:4057-4093.
24. 3 receptors. J Pharmacol Exp Ther 310:407-416.
25. 2/3 receptors, reduces chronic inflammatory and neuropathic pain in rats. Proc Natl Acad Sci USA 99:17179-17184.
26. + release. Am J Cell Physiol 286:C1100-C1108.
27. Kim SH and Chung JM (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-363.
28. 7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 168:6436-6445.
29. 2 receptor and TRPV channel by ATP: implications for ATP induced pain. Cell Mol Neurobiol 25:819-32.
30. th Annual Society for Neuroscience Meeting; 2005 Nov 12-16; Washington, DC. Society for Neuroscience, Washington, DC.
31. Lynch JJ 3rd, Wade CL, Mikusa JP, Decker MW, and Honore P (2005) ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model. Eur J Pharmacol 509:43-48.
32. Lynch KJ, Touma E, Niforatos W, Kage KL, Burgard EC, van Biessen T, Kowaluk EA, and Jarvis MF (1999) Molecular and functional characterization of human P2X(2) receptors. Mol Pharmacol 56:1171-1181.
33. Maier SF, Wietelak EP, Martin D, and Watkins LR (1993) Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 623:321-324.
34. Murgia M, Hanau S, Pizzo P, Rippa M, and Di Virgilio F (1993) Oxidized ATP: an irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biol Chem 268:8199-81203.
35. th Annual Society for Neuroscience Meeting; 2005 Nov 12-16; Washington, DC. Society for Neuroscience, Washington, DC.
36. 7 antagonists. J Med Chem 49:3659-3666.
37. North AR (2002) Molecular Physiology of P2X Receptors. Physiol Rev 82:1013-1067.
38. 7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase. J Neurosci 21:7135-7142.
39. 7-receptors activation in Mueller glial cells from the human retina. J Neurosci 20:5965-5972.
40. 7 mediates superoxide production in primary microglia and is upregulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem 278:13309-13317.
41. Perregaux DG and Gabel CA (1994) Interleukin-1β maturation and release in response to ATP and nigericin. J Biol Chem 269:15195-15203.
42. 7 receptor. Bioorg Med Chem Lett 14:5709-5712.
43. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, and Woolf CJ (1995) Contribution of interleukin-1 to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 115:1265-1275.
44. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, and Woolf CJ (2001) Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature (Lond) 410:471-75.
45. 7 receptor expression in rodent brain. J Neurosci 24:6307-6314.
46. 7 receptors. J Biol Chem 276:125-132.
47. Sommer C, Petrausch S, Lindenlaub T, and Toyka K (1999) Neutralizing antibodies to interleukin1-receptor reduce pain-associated behavior in mice with experimental neuropathy. Neurosci Lett 270:25-28.
48. Surprenant A, Rassendren F, Kawashima E, North RA, and Buell G (1996) The cytolytic P2z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science (Wash DC) 272:735-738.
49. Tominaga M, Wada M, and Masu M (2001) Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci USA 98:6951-6956.
50. Touzani O, Boutin H, LeFeurve R, Parker L, Miller A, Luheshi G, and Rothwell N (2002) Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type 1 receptor. J Neurosci 22:38-43.
51. 4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature (Lond) 424:778-783.
52. Verhoef PA, Estacion M, Schilling W, and Dubyak GR (2003) P2X7 Receptor-dependent blebbing and the activation of Rho-effector kinases, caspases, and IL-1 release. J Immunol 170:5728-5738.
53. Wolf G, Yirmiya R, Goshen I, Iverfeldt K, Holmlund L, Takeda K, and Shavit Y (2004) Impairment of interleukin-1 (IL-1) signaling reduces basal pain sensitivity in mice: genetic, pharmacological and developmental aspects. Pain 104:471-480.
54. Woolf CJ, Allchorne A, Safieh-Garabedian B, and Poole S (1997) Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 121:417-424.
55. 7 receptors in non-neuronal cells of rat dorsal root ganglion. Brain Res 1052:63-70.